Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...
Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...
LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors
The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...
Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit
China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...
InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma
US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...
Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...
Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...
AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...
Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma
US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China
Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...
AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...